Michelle is an award-winning thought-leader, speaker, advocate, and health technology entrepreneur.  She has established four start ups including Trialkey which applies artificial intelligence to improving and predicting clinical trial results.

Commencing in allied health, Michelle’s career spans clinical and administrative roles in public and private health, commercial and executive roles with biotech, pharmaceutical, and medical organisations, as well as and leading a biotech peak-body and influencing legislation and regulation in healthtech.

Michelle moved from the corporate world to found her first startup in 2014, successfully selling that business three years later and going on to found AI health tech company Opyl Ltd in 2019 (ASX:OPL).

The appropriate application of AI in healthcare and the role of ethics and digital leadership in technology development is a key issue that Michelle is renowned for as a champion and advocate.

Michelle is an experienced non-executive director on several boards (Praxis Australia, Cancer Trials Australia, and Medtech Actuator) and is co-founder of not-for-profit advocacy organisation, Women in STEMM Australia.

Michelle is a Victorian Honour Roll for Women inductee, Victorian Telstra Businesswoman and Entrepreneur of the Year, and a winner of Westpac’s 200 Businesses of Tomorrow.

Michelle has an undergraduate degree in applied science, postgraduate qualifications in business and product management, a Global Executive MBA, is a GAICD and FAIM.

Professor Lyndell Lim is a uveitis and medical retina subspecialist and leads CERA’s Uvietis and Vascular Retinal Disease Research.

After completing her ophthalmology training in Melbourne, Professor Lim then completed two Fellowships – one in medical retina at the Royal Victorian Eye and Ear Hospital, and one in uveitis/ocular inflammatory disease at the Casey Eye Institute, Portland, Oregon, USA.

Prof Lim’s main research interests are clinical studies in the field of uveitis and ocular immunology, and diabetic retinopathy. Her team runs both investigator-initiated and sponsored clinical trials that aim to investigate new treatments in a variety of ophthalmic diseases.

Marios Constantinou is the Chief Clinical Operations Officer at Cerulea.

He is an allied health clinician (Orthoptist) with over 20 years’ experience in clinical trials (Pharmaceutical and Investigator Initiated).

His extensive years of experience has afforded him of the opportunity to work with many leading Centre for Eye Research Australia (CERA) investigators and study teams, and sponsor companies. Over the last 10 years, he has been responsible for managing CERAs Clinical Trials Centre Operations, leading a high-calibre clinical trial team across all ophthalmic indications and trial phases. He has proven capabilities in clinical operations, quality assurance, clinical trial coordination and financial management.

Our Board Directors provide strategic oversight and guidance, contributing extensive expertise and knowledge of clinical trials, medical research and  biopharmaceutical and device development.

Cerulea Clinical Trials’ state-of-the-art facilities and experienced team deliver innovation and excellence in ophthalmic clinical trials.